Assuntos
Anti-Inflamatórios/uso terapêutico , Fígado Gorduroso/tratamento farmacológico , Ácido Glicirrízico/uso terapêutico , Lipossomos , Cirrose Hepática/tratamento farmacológico , Alanina Transaminase/sangue , Animais , Anti-Inflamatórios/farmacologia , Aspartato Aminotransferases/sangue , Gorduras na Dieta/administração & dosagem , Modelos Animais de Doenças , Medicamentos de Ervas Chinesas/administração & dosagem , Medicamentos de Ervas Chinesas/farmacologia , Medicamentos de Ervas Chinesas/uso terapêutico , Fígado Gorduroso/etiologia , Fígado Gorduroso/patologia , Ácido Glicirrízico/administração & dosagem , Ácido Glicirrízico/farmacologia , Injeções , Fígado/efeitos dos fármacos , Fígado/patologia , Cirrose Hepática/etiologia , Cirrose Hepática/patologia , Masculino , Fenantrolinas/administração & dosagem , Fenantrolinas/farmacologia , Fenantrolinas/uso terapêutico , Distribuição Aleatória , Ratos , Ratos Sprague-Dawley , Salvia miltiorrhiza , Resultado do TratamentoRESUMO
OBJECTIVE: To observe cytotoxic T lymphocytes (CTL) responses induced by immunization of mice with hepatis B small surface antigen (S-HBsAg). METHODS: BALB/c(H-2d) mice were injected intraperitoneally with S-HBsAg at the doses ranging from 0-5 microg with a booster injection 2 weeks later. Four weeks after the booster immunization, the specific cytotoxic reactivity of the spleen lymphocytes isolated from the immunized mice, following stimulation by S-HBsAg specific CTL epitope peptide in vitro, with 51Cr-labeled P815 cells treated with the peptide was observed. RESULTS: The percentage of specific release of 51Cr in mice immunized with S-HBsAg at the doses of 0, 0.65, 1.25, 2.5, and 5 microg was 31.21%+/-9.23%, 42.36%+/-19.32%, 91.21%+/-22.97%, 69.25%+/-24.13% and 51.49%+/-21.661% respectively. In mice receiving the only primary vaccination, the corresponding percentage was 27.34%+/-14.25%, 32.27%+/-15.35%, 56.28%+/-24.35%, 44.34%+/-18.65% and 40.76+/-56% respectively. CONCLUSION: Immunization with S-HBsAg efficiently elicits CTL response in BALB/c mice in a dose-dependent manner and enhanced by booster immunization.
Assuntos
Antígenos de Superfície da Hepatite B/imunologia , Vacinas contra Hepatite B/imunologia , Linfócitos T Citotóxicos/imunologia , Animais , Feminino , Imunização , Camundongos , Camundongos Endogâmicos BALB CRESUMO
To investigate the modification of recombinant human augmenter of liver regeneration (rhALR) by the urea in purification processes and the biological activity of rhALR and modified rhALR, the molecular weight of proteins and tryptic peptides were determined by matrix-assisted laser desorption time of flight mass spectrometry (MALDI-TOF-MS), and the biological activity of rhALR and modified rhALR was also observed by in vivo experiments. A 30 kD homodimer of rhALR was purified under denaturing conditions. The molecular weight of rhALR is 30 780 if urea was used to denature the inclusion bodies; when the denaturant was guanidine hydrochloride, the molecular weight of rhALR was 30 087. The results of MALDI-TOF-MS of digested rhALR that have been modified by urea showed that peptides that contained lysyl were 43 larger than the theoretical value. Proteins purified by different processes were all able to promote the survival rate of CCl(4)-intoxicated mice. It could be concluded that cyanate, the cleavage product of urea, could react with the epsilon-amino group of lysyl in rhALR, and the modified rhALR had the same biological activity as natural rhALR.